액체 충전 하드 캡슐 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the liquid filled hard capsules market size is projected to be USD 1.9 billion in 2025, USD 1.99 billion in 2026, and reach USD 2.85 billion by 2031, growing at a CAGR of 7.45% from 2026 to 2031.

This report is Segmented by Shell Material (Gelatin, HPMC, Pullulan/Other Cellulose), Filling State (Oil-Based Liquids, Suspensions, Semi-solid/Hot-melt Fills, and More), Sealing Method (Banding, Lock-Only, and More), End Use (Rx Pharmaceuticals, OTC, and More), Release Profile (Immediate Release, Modified Release), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Liquid Filled Hard Capsules Market Trends and Insights

Bioavailability Push For Poorly Soluble APIs Drives Liquid-Fill Adoption

A large share of new small-molecule candidates presents low aqueous solubility, which steers development teams toward lipid-based liquid-fill strategies such as SEDDS and SMEDDS to increase dissolution and absorption in the gastrointestinal tract. These systems combine oils with surfactants and co-surfactants to spontaneously form fine emulsions on contact with intestinal fluids, which increases interfacial area and supports more predictable uptake. In the liquid filled hard capsules market, this approach aligns with the objective of reducing variability in drug exposure for BCS Class II and IV compounds, which can otherwise show erratic plasma profiles when delivered as conventional tablets.

Manufacturers pair these fills with shell selections that avoid cross-linking and moisture-driven degradation so that dissolution kinetics remain consistent during shelf life. Regulatory frameworks and compendial standards reinforce quality-by-design practices for liquid oral dosage forms, improving the predictability of development and scale-up paths for these capsule formats. As a result, the liquid filled hard capsules market is positioned to capture a larger share of pipeline reformulations that target solubility-limited exposure.

Nutraceutical Growth Propels Capsule Demand Across Consumer Segments

Consumers continue to prefer single-dose formats that are easy to swallow with perceived faster uptake, which has lifted capsule-based delivery for oils, vitamins, enzymes, and probiotics in retail channels. In the liquid filled hard capsules market, brands are leveraging fusion sealing and enhanced oxygen barriers to protect oxidation-sensitive actives like omega-3, CoQ10, and certain botanicals while also enhancing tamper-evidence. Probiotic and enzyme formulations are adopting HPMC shells with delayed-release designs so that sensitive ingredients survive gastric conditions before releasing in the intestine, which strengthens efficacy positioning without adding a coating operation.

As manufacturers expand dose ranges for categories like collagen or multi-ingredient blends, portion sizes and ease of regimen adherence remain central to packaging and format decisions in retail lines. These user-centric attributes are helping the liquid filled hard capsules market capture growth opportunities where taste masking, stability, and clean-label shell certifications are key differentiators. As nutraceutical portfolios diversify, suppliers with integrated shell, sealing, and fill expertise are positioned to translate new concepts into shelf-stable SKUs at speed.

Specialized Sealing Adds Cost And Process Complexity

Liquid-filled formats often require banding or fusion sealing as part of container-closure integrity, which adds steps that can raise capital and operating burdens compared to conventional hard capsules. In the liquid filled hard capsules market, fusion systems that create hermetic, continuous seams deliver premium protection, yet they call for dedicated equipment, validation, and operator skill that not all sites maintain. As lines become more advanced, firms must validate in-line controls and inspection steps that ensure weight, seal integrity, and appearance meet specifications in real time. This escalates the quality management footprint, which can lengthen tech transfers for smaller batches or frequent SKU changeovers. Sponsors that need premium tamper-evidence and oxidative protection gain shelf-life and quality benefits, but the added complexity may weigh on programs where price competition is tight. The trade-off shapes facility strategies and outsourcing choices across the liquid filled hard capsules market.

Other drivers and restraints analyzed in the detailed report include:

1. Advances In Liquid Dosing And Sealing Accuracy
2. HPMC Adoption For Moisture-Sensitive And Vegetarian Formulations
3. Excipient-Shell Interactions Demand Extensive Validation Protocols

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Gelatin capsules held 73.24% of the liquid filled hard capsules market share in 2025, supported by mature processing infrastructure and well-understood dissolution behavior across common oil and suspension fills. This installed base keeps gelatin central to high-volume programs where formulations avoid excipient chemistries that could drive cross-linking. Sponsors value streamlined qualification when working with established gelatin supply networks and site-level experience in banding workflows. HPMC continues to expand faster because of inherent resistance to aldehyde-driven cross-linking, lower shell moisture, and its suitability for delayed or modified-release designs, all of which increase formulation headroom. Certification footprints that include non-GMO, halal, and vegan claims also help HPMC unlock labeled product opportunities that are central to many consumer portfolios. Within the liquid filled hard capsules market, the dynamic between gelatin's scale economics and HPMC's functional and labeling advantages will continue to shape shell selection decisions through 2031.

HPMC is projected to post an 8.51% CAGR through 2031 as more moisture-sensitive APIs, probiotics, enzymes, and solvent-containing fills shift away from gelatin to maintain stability and predictable release. Suppliers have invested in thermogelation processes and polymer-engineering advances that deliver pH-independent dissolution and consistent performance across liquid-fill modalities. In the liquid filled hard capsules industry, this capability lets formulators design products that combine delayed-release features with lipid vehicles while maintaining label claims that matter in consumer-facing channels. Gelatin remains a strong fit for stable, neutral-pH oils and simpler suspensions, so portfolio-specific criteria continue to drive hybrid procurement strategies at large buyers. Over time, rising comfort with HPMC in regulated products and the expansion of certified supply may gradually rebalance shares in favor of plant-based shells.

Oil-based liquid fills accounted for 45.32% of the liquid filled hard capsules market size in 2025, reflecting their central role in vitamins, oils, and hormone products where solubilization is straightforward. Operators continue to favor oil vehicles for their process simplicity, stable handling windows, and broad compatibility with both gelatin and HPMC shells. Where APIs demand stronger solubilization, programs migrate toward engineered emulsifying systems that deliver higher exposure with tighter inter-patient variability. This is where the liquid filled hard capsules market is seeing the greatest formulation innovation, because shell, seal, and fill must be tuned together to preserve performance across shelf life. In parallel, equipment providers have improved throughput, in-line control, and temperature management for hot fills and viscous systems that need tight processing windows.

Self-emulsifying SEDDS/SMEDDS are projected to grow at a 9.85% CAGR through 2031, reinforced by peer-reviewed evidence that lipid microemulsions improve solubilization and exposure for difficult APIs. The ability to target droplet sizes in the nano to submicron range increases interfacial area, which helps drive consistent absorption even under variable fed-state conditions. Suspension and hot-melt applications maintain clear roles where actives have low oil solubility or benefit from semi-solid matrices, yet they rely more heavily on robust process controls to manage sedimentation and thermal profiles. As pipelines evolve toward complex delivery goals, the liquid filled hard capsules market will keep allocating greater share to emulsifying systems that can integrate release control with solubilization strategies.

Geography Analysis

North America held 34.56% of the liquid filled hard capsules market in 2025, supported by a strong base of pharmaceutical sponsors, established capsule manufacturing, and mature regulatory systems for oral dosage forms. U.S. cGMP requirements and container-closure integrity expectations have helped standardize quality and documentation practices for liquid-fill programs. Capsules with fusion sealing and HPMC shells are increasing in projects where oxidative stability and label claims support premium therapies and consumer products. The region's installed base of high-throughput lines supports large-volume runs across both Rx and OTC, which anchors capacity for launches and reformulations. This ecosystem positions North America to remain an influential buyer and producer through the forecast window.

Asia-Pacific is projected to be the fastest-growing region at a 9.32% CAGR through 2031, reflecting strong manufacturing capability and increasing adoption of premium sealing and shell options in both pharmaceutical and nutraceutical pipelines. Regional suppliers and global multinationals are expanding capacity and technology stacks to serve local and export demand with higher integrity formats. As sponsors localize production and upgrade equipment, high-speed lines with in-line controls are becoming more common in leading hubs. HPMC adoption is rising alongside demand for vegetarian and halal certification, which supports retail and Rx use cases across major markets. This combination of quality, speed, and certification breadth supports the region's outperformance in the liquid filled hard capsules market.

Europe shows steady growth under rigorous quality standards that favor producers with validated processes for liquid fills, fusion sealing, and advanced release designs. Activity includes capacity additions in packaging and integrated services that support both pharma and consumer health customers. HPMC uptake is strong in use cases that require moisture management or expand labeled claims for vegetarian and halal preferences. With a high bar for documentation, extractables and leachables testing, and in-process controls, European manufacturers have built operating models that align with complex liquid-fill demands. This keeps the region well positioned in regulated markets while also serving global supply needs in the liquid filled hard capsules market.

1. ACG Worldwide
2. Aenova Group
3. Ascendia Pharmaceutical Solutions
4. Catalent, Inc
5. CapsCanada
6. Farmacapsulas
7. HealthCaps India Ltd
8. I.M.A. Industria Macchine Automatiche S.p.A.
9. Lonza Group
10. MG2 s.r.l.
11. Qualicaps
12. Roxlor LLC
13. SaintyCo
14. SEJONG PHARMATECH
15. Sirio Pharma
16. Suheung (EMBO CAPS)
17. Sunil HealthCare Limited
18. Syntegon Technology
19. Vantage Nutrition

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Bioavailability Push for Poorly Soluble APIs (Lipid-Based Fills, SEDDS/SMEDDS)
  • 4.2.2 Nutraceutical Growth and Capsule Preference
  • 4.2.3 Advances in Liquid Dosing and Sealing Accuracy
  • 4.2.4 HPMC Adoption for Moisture-Sensitive and Vegetarian Formulations
  • 4.2.5 High-Throughput Capsule Machinery Enabling LFHC Scale-Up
  • 4.2.6 Banding/Fusion Sealing Enabling Tamper-Evidence and Premiumization
• 4.3 Market Restraints
  • 4.3.1 Specialized Sealing Adds Cost and Process Complexity
  • 4.3.2 Excipient-Shell Compatibility and Regulatory Validation Burdens
  • 4.3.3 Gelatin Supply and Cultural Constraints Create Volatility
  • 4.3.4 Oxygen/Moisture Ingress Risk Without Advanced Sealing/Packaging
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Shell Material
  • 5.1.1 Gelatin
  • 5.1.2 HPMC
  • 5.1.3 Pullulan / Other Cellulose
• 5.2 By Filling State
  • 5.2.1 Oil-based liquids
  • 5.2.2 Suspensions
  • 5.2.3 Semi-solid / Hot-melt fills
  • 5.2.4 Self-emulsifying (SEDDS/SMEDDS)
• 5.3 By Sealing Method
  • 5.3.1 Banding
  • 5.3.2 Fusion sealing / LEMS microspray
  • 5.3.3 Lock-only
• 5.4 By End Use
  • 5.4.1 Rx Pharmaceuticals
  • 5.4.2 OTC
  • 5.4.3 Nutraceuticals / Dietary Supplements
• 5.5 By Release Profile
  • 5.5.1 Immediate Release
  • 5.5.2 Modified Release (Sustained / Enteric)
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 ACG
  • 6.3.2 Aenova Group
  • 6.3.3 Ascendia Pharmaceutical Solutions
  • 6.3.4 Catalent, Inc
  • 6.3.5 CapsCanada
  • 6.3.6 Farmacapsulas
  • 6.3.7 HealthCaps India Ltd
  • 6.3.8 I.M.A. Industria Macchine Automatiche S.p.A.
  • 6.3.9 Lonza
  • 6.3.10 MG2 s.r.l.
  • 6.3.11 Qualicaps
  • 6.3.12 Roxlor LLC
  • 6.3.13 SaintyCo
  • 6.3.14 SEJONG PHARMATECH
  • 6.3.15 Sirio Pharma
  • 6.3.16 Suheung (EMBO CAPS)
  • 6.3.17 Sunil HealthCare Limited
  • 6.3.18 Syntegon Technology GmbH
  • 6.3.19 Vantage Nutrition

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment